Prescribers have said that it’s difficult to stop medications when prescribing guidelines only talk about starting them. The “Deprescribing Guidelines for the Elderly” project developed evidence-based deprescribing guidelines to support clinicians in safely reducing or stopping medications. We conducted a national survey to identify priorities for deprescribing guidelines. Then, we used an evidence-based approach to develop deprescribing guidelines for three specific drug classes — proton pump inhibitors, benzodiazepine receptor agonists, and antipsychotics. We piloted these guidelines in three long-term-care and three Family Health Teams in the Ottawa area in Ontario, Canada.
More about this project can be found here.
Funder (2013-2016): This research/study is supported by the Ontario Pharmacy Research Collaboration (OPEN) and funded by the Government of Ontario Health Services Research Fund.
- PPI deprescribing guideline In Press, Canadian Family Physician
- PPI deprescribing algorithm
- PPI deprescribing pamphlet
- PPI deprescribing patient decision-aid Coming soon!
- BZRA deprescribing guideline Coming soon!
- BZRA deprescribing algorithm
- BZRA deprescribing pamphlet
- AP deprescribing guideline Coming soon!
- AP deprescribing algorithm
- Deprescribing guidelines methods publication
- Developing your own evidence-based deprescribing guideline instruction manual Coming soon!
- Deprescribing self-efficacy survey
- Farrell B, Richardson L, Raman-Wilms L, de Launay D, Alsabbagh MW, Conklin J. Self-efficacy for deprescribing: A survey for health care professionals using evidence-based deprescribing guidelines. Res Social Adm Pharm, 2017; Jan 28; pii: S1551-7411(17)30055-4. doi: 10.1016/j.sapharm.2017.01.033
- Thompson W, Farrell B, Welch V, Tugwell P, Bjerre LM. Should I continue taking my acid reflux medication? Design of a pilot before/after study evaluating a patient decision aid. Can Pharm J, 2017; Jan-Feb; 150(1): 19-23.
- Thompson W, Quay TA, Rojas-Fernandez C, Farrell B, Bjerre LM. Atypical antipsychotics for insomnia: A systematic review and meta-analysis protocol. Sleep Med, 2016; Jun; 22: 13-7.
- Farrell B, Pottie K, Rojas-Fernandez CH, Bjerre LM, Thompson W, Welch V. Methodology for developing deprescribing guidelines: Using evidence and GRADE to guide recommendations for deprescribing. PLoS One, 2016; 11(8): e0161248. doi:10.1371/journal.pone.016124.
- Thompson W, Hogel M, Li Y, Thavorn K, O’Donnell D, McCarthy L, Dolovich L Black C, Farrell B. Effect of a proton pump inhibitor deprescribing guideline on drug usage and costs in long-term care. JAMDA, 2016; 17(7), 673.e1 – 673.e4.
- Conklin J, Farrell B, Ward N, McCarthy L, Irving H, Raman-Wilms L. Developmental evaluation as a strategy to enhance the uptake and use of deprescribing guidelines: protocol for a multiple case study. Implement Sci, 2015; Jun 18;10(1):91. doi: 10.1186/s13012-015-0279-0.
- Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: A modified Delphi process. PLOS One, 2015; 10(4): e0122246.
- Boghossian TA, Rashid FJ, Welch V, Rojas-Fernandez C, Moayyedi P, Pottie K, Walsh K, Pizzola L, Thompson W, Farrell B. Deprescribing versus continuation of chronic proton pump inhibitor use in adults (protocol). Cochrane Database Syst Rev, 2015; Issue 11, article number CD011969.